Not all products and indications may be licensed in your country. For more information contact your local representative.
In the EU, the following products are registered under different names: EMSCULPT (BTL EMSCULPT), EXION (BTL-785F), EMFACE (BTL-785F), EMSELLA (BTL EMSELLA), VANQUISH ME (BTL VANQUISH ME), EXILIS (EXILIS ELITE).
EMSCULPT NEO® is intended for treatment of obesity by fat reduction through neuromuscular stimulation, radiofrequency induced lipolysis and increase of the blood flow. When EMSCULPT NEO is connected with the optional accessory EMSELLA Chair Applicator, the intended purpose is extended as follows: to provide pelvic floor muscle strengthening for treatment of urinary incontinence in male and female patients. EMSCULPT® is intended for the treatment of obesity by fat reduction through neuromuscular stimulation and increase of blood flow. When EMSCULPT is connected with the optional accessory EMSELLA Chair Applicator, the intended purpose is extended as follows: to provide pelvic floor muscle strengthening for treatment of urinary incontinence in male and female patients. BTL-785F (EMFACE TECHNOLOGY) is intended for aesthetic procedures such as facial rejuvenation and contouring by wrinkles reduction and skin laxity improvement by means of toning and lifting of muscles and skin. BTL-785F with EXION™ Body applicator BTL-785-1 is intended for treatment of obesity by means of controlled reduction of fat cells, induced by radiofrequency field in cooperation with ultrasound. BTL-785F with EXION™ Face applicator BTL-785-2 is intended for treatment of obesity by means of controlled reduction of fat cells, induced by radiofrequency field in cooperation with ultrasound and for treatment of wrinkles and rhytides. BTL-785F with EMFEMME applicator BTL-785-3 is intended for the treatment of sexual dysfunction after vaginal delivery by means of improvement of vaginal laxity. BTL-785F with EXION™ Fractional RF applicator BTL-785-4 is intended for use in dermatologic procedures such as treatment of acne, scars, solar elastosis and hyperhidrosis. EMSELLA® is intended to provide pelvic floor muscle strengthening for treatment of urinary incontinence in male and female patients. EMTONE® is a radio-frequency combined with targeted pressure energy device for treatment of obesity and localized obesity by fat reduction, skin laxity treatment, skin regeneration, treatment of gynoid lipodystrophy, alleviation of pain and alleviation of muscle spasms The Exilis Ultra 360 is intended for treatment of obesity by means of controlled reduction of fat cells, induced by radiofrequency field in cooperation with ultrasound and for treatment of sexual dysfunction after vaginal delivery by means of improvement of vaginal laxity. Vanquish® / BTL Vanquish ME is a non-invasive therapeutic device intended for the treatment of obesity by means of fat reduction achieved through deep tissue heating and enhancement of blood flow and metabolism by high-frequency electromagnetic field.
BTL®, EXILITE®, EXILIS®, EXION™, VANQUISH®, UNISON®, CELLUTONE®, CORE TO FLOOR®, EMSCULPT®, EMSCULPT NEO®, EMFACE®, EMSELLA®, EMFEMME 360®, EMBODY®, EMTONE® and HIFEM® are registered trademarks in the United States of America, the European Union or other countries. The products, the methods of manufacture or the use may be subject to one or more U.S. or foreign patents or pending applications. Trademarks EMFACE, EMSCULPT, EMSCULPT NEO, EMSELLA, EMTONE, EMFEMME 360, and EMBODY are associated with the EM™ family of products and services. *Data on file.
Results and patient experience may vary. As with any medical procedure, ask your doctor if the procedure is right for you.
This site is not intended for US customers. US customers, click here.
We protect your personal data. Read more.
© 2024, BTL Group of Companies. All rights reserved.
Terms of Use
| Privacy Statement
| GDPR